Nycomed Articles
USA Lags Foreign Approvals, PhRMA Demonstrates
16 October 1995
Astra AB: Nycomed AB pantoprazole injunction
2 October 1995
Hafslund Nycomed/Diatech nuclear imaging agent deal
21 August 1995
Best Ever Results For Hafslund Nycomed
7 August 1995
European Drug Sector Still Undervalued, Says Broker
31 July 1995
Hafslund Nycomed: European to Global Player
12 June 1995
European stock comment
15 May 1995
Good First Quarter For Hafslund Nycomed
15 May 1995
Hafslund Nycomed Agreement In USA
13 March 1995
Hafslund Nycomed Net Hit By Sterling Buy
20 February 1995
Shire Expands Product Lines
13 February 1995
Oligopoly The Future For The Pharma Industry
2 January 1995
Guerbert Opts For Independence
12 December 1994
Hafslund Nycomed: Improved Sales, Flat Profits
14 November 1994
Alza Agreement
7 November 1994
Unmet Needs In Cardiovascular Markets
24 October 1994
US Lay-Offs Follow Sterling Break Up
10 October 1994
Sonus Plans EchoGen NDA For Early 1995
26 September 1994
Hafslund And Byk Gulden Settle Dispute
26 September 1994
Nycomed Forms JV In China
19 September 1994
Change Is An Opportunity, SB Chief Tells IFPMA
19 September 1994
Sanofi Preparing Bioactivities Sell-Offs
12 September 1994
HAFSLUND NYCOMED APPOINTMENT
15 August 1994
Hafslund To Buy Sterling Diagnostics
15 August 1994
Hafslund Nycomed's 1st Half As Expected
8 August 1994
H NYCOMED MOVES TO TOP OF IMAGING
4 July 1994
HAFSLUND NYCOMED PROFITS DECLINE
23 May 1994
HAFSLUND NYCOMED IN CHINA VENTURE
21 March 1994
HAFSLUND RESULTS ABOVE EXPECTATION
21 February 1994
HAFSLUND NYCOMED ACQUISITION
7 February 1994
ALBUNEX APPROVED IN EUROPE
7 February 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
FIRST APPROVAL FOR NYCOMED'S ABDOSCAN
20 December 1993
HAFSLUND NYCOMED EXPECTS FLAT PROFITS
13 December 1993
IRINOTECAN BACKED IN JAPAN AMID CONCERNS
13 December 1993
HAFSLUND NYCOMED ACQUIRES TEST RIGHTS
6 December 1993
NYCOMED FILES FOR LORNOXICAM
22 November 1993
ALBUNEX GAINS FIRST APPROVAL IN JAPAN
8 November 1993
NYCOMED APPOINTMENT
23 August 1993
HAFSLUND NYCOMED FIRST HALF SALES UP
9 August 1993
DAIICHI ENTERING NEW PRODUCT PHASE
26 July 1993
GROWTH AHEAD ALTANA WITH REBOUND IN 1994
7 June 1993
HAFSLUND NYCOMED 1ST QTR PROFIT RISE
10 May 1993
NYCOMED IMAGING APPROVAL
19 April 1993
NYCOMED TO EXPAND IMAGING R&D
15 March 1993
SIGNIFICANT MOVES BY PHARMA COS IN FT 500
1 March 1993
NYCOMED IMAGING AGENT APPROVED
22 February 1993
HAFSLUND NYCOMED "IN A STRONG GROWTH PHASE"
22 February 1993
PROFITS UP 17% IN 1992 AT NYCOMED
15 February 1993
JAPANESE PRODUCT NEWS IN BRIEF
1 February 1993
OMNISCAN IN THE USA
18 January 1993
1ST SUBMISSION FOR NYCOMED'S OMP
4 January 1993
1992 SEES SMALLER COMPANY MERGERS
4 January 1993
CONTRAST MEDIA MARKET SLOWDOWN EXPLAINED
7 December 1992
HAFSLUND NYCOMED DOWNGRADED
7 December 1992
HAFSLUND NYCOMED 9 MTH PROFIT UP 25%
9 November 1992
OMNISCAN APPROVED IN UK
5 October 1992
CONTRAST MEDIA MARKET TO 2000
7 September 1992
HAFSLUND NYCOMED BIG BOARD LISTING
29 June 1992
DANISH OTC MARKET UPDATE
18 May 1992
HAFSLUND NYCOMED PROFITS JUMP 46%
18 May 1992
HYDRO PHARMA TAKEOVER
20 April 1992
HAFSLUND NYCOMED'S CONTRAST AGENT
20 April 1992
HAFSLUND GOES FOR ITALIAN MARKET
13 April 1992
HAFSLUND NYCOMED 46% OPERATING PROFIT JUMP
17 February 1992
FEWER ACQUISITIONS AND MERGERS IN 1991
6 January 1992
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
